MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Mutua de Terrassa
Terrassa, EspañaPublicaciones en colaboración con investigadores/as de Mutua de Terrassa (3)
2014
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111